This company listing is no longer active
HEXO Past Earnings Performance
Past criteria checks 0/6
HEXO's earnings have been declining at an average annual rate of -42.2%, while the Pharmaceuticals industry saw earnings growing at 14.8% annually. Revenues have been growing at an average rate of 39.8% per year.
Key information
-42.2%
Earnings growth rate
-4.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 39.8% |
| Return on equity | -191.4% |
| Net Margin | -220.1% |
| Last Earnings Update | 30 Apr 2023 |
Recent past performance updates
Recent updates
Hexo to produce Mike Tyson's cannabis brand's products in Canada
Aug 30Canopy Growth, Tilray other Canadian cannabis names up amid WallStreetBets chatter
Aug 17HEXO receives additional 180 calendar day grace period for regaining compliance
Jul 28HEXO wins shareholder approval for note transaction with Tilray
Jul 05HEXO: Undervalued, But With Certain Dilution Risks
Apr 28HEXO Q1 Earnings: Not A Great Path Forward
Dec 14Revenue & Expenses Breakdown
How HEXO makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Apr 23 | 124 | -273 | 61 | 1 |
| 31 Jan 23 | 148 | -301 | 86 | 1 |
| 31 Oct 22 | 177 | -1,013 | 105 | 3 |
| 31 Jul 22 | 191 | -1,074 | 122 | 3 |
| 30 Apr 22 | 187 | -1,042 | 128 | 4 |
| 31 Jan 22 | 164 | -918 | 109 | 4 |
| 31 Oct 21 | 144 | -228 | 96 | 4 |
| 31 Jul 21 | 124 | -115 | 80 | 4 |
| 30 Apr 21 | 112 | -214 | 75 | 4 |
| 31 Jan 21 | 112 | -213 | 75 | 4 |
| 31 Oct 20 | 96 | -491 | 78 | 4 |
| 31 Jul 20 | 81 | -546 | 91 | 5 |
| 30 Apr 20 | 69 | -423 | 115 | 7 |
| 31 Jan 20 | 60 | -411 | 119 | 6 |
| 31 Oct 19 | 56 | -117 | 114 | 5 |
| 31 Jul 19 | 48 | -70 | 105 | 3 |
| 30 Apr 19 | 34 | -35 | 73 | 0 |
| 31 Jan 19 | 22 | -30 | 54 | 0 |
| 31 Oct 18 | 9 | -34 | 41 | 0 |
| 31 Jul 18 | 5 | -23 | 23 | 0 |
| 30 Apr 18 | 4 | -12 | 15 | 0 |
| 31 Jan 18 | 4 | -22 | 12 | 0 |
| 31 Oct 17 | 4 | -14 | 9 | 0 |
| 31 Jul 17 | 4 | -12 | 7 | 0 |
| 30 Apr 17 | 4 | -15 | 7 | 0 |
| 31 Jan 17 | 4 | -3 | 5 | 0 |
| 31 Oct 16 | 3 | -3 | 4 | 0 |
| 31 Jul 16 | 2 | -3 | 4 | 0 |
| 31 Jul 15 | 0 | -3 | 2 | 0 |
Quality Earnings: HEXO is currently unprofitable.
Growing Profit Margin: HEXO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: HEXO is unprofitable, and losses have increased over the past 5 years at a rate of 42.2% per year.
Accelerating Growth: Unable to compare HEXO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: HEXO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-6.3%).
Return on Equity
High ROE: HEXO has a negative Return on Equity (-191.4%), as it is currently unprofitable.